22-26 June, 2022 London
![]() |
![]() |
![]() |
![]() |
FRI-001 | Obeticholic acid exacerbates the liver fibrosis of bile duct ligation model by inducing the liver expression of osteopontin | Jie Wang | ![]() |
![]() |
|||
FRI-004 | Two different types of COVID-19 vaccines and serial liver biochemistries | Grace Wong | ![]() |
![]() |
|||
FRI-005 | Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study | Lucia Parlati | ![]() |
![]() |
|||
FRI-007 | Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study | Lucia Parlati | ![]() |
![]() |
|||
THU-010 | Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study | Axel Wester | ![]() |
![]() |
|||
SAT-011 | NAFLD-induced encephalopathy is associated with low-grade brain tissue hypoxia and inflammation, as well as cerebrovascular, glial, metabolic and behavioural alterations | Anna Hadjihambi | ![]() |
![]() |
|||
THU-016 | Patient and system-level factors underline offering and acceptance of alcohol use disorder therapy in veterans with cirrhosis | Jasmohan S Bajaj | ![]() |
![]() |
|||
THU-023 | Active alcohol misuse is linked with lower short-chain fatty acid producing microbiota in a matched study of 450 patients with cirrhosis | Jasmohan S Bajaj | ![]() |
![]() |
|||
SAT-024 | Isoleucine and valine correct hepatic lipid processing, reduce liver steatosis and suppress inflammation in obese mice with manifest NASH | Eveline Gart | ![]() |
![]() |
|||
SAT-025 | Butyrate protects against diet-induced NASH and liver fibrosis and suppresses specific non-canonical TGFB signaling pathways in human hepatic stellate cells | Eveline Gart | ![]() |
![]() |
|||
FRI-026 | Three COVID-19 medications - remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir - and serial liver biochemistries in 22,456 subjects | Grace Wong | ![]() |
![]() |
|||
THU-035 | Prophylaxis of withdrawal syndrome decreases mortality in patients with alcohol-associated hepatitis | David Marti-Aguado | ![]() |
![]() |
|||
FRI-036 | Impact of alcohol use on the diagnostic performance of serum-based indices for fatty liver disease | Oscar Danielsson | ![]() |
![]() |
|||
FRI-047 | Radiowater perfusion PET of the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade | Olof Eriksson | ![]() |
![]() |
|||
FRI-049 | Association of the biological age and the level of global deoxyribonucleic acid methylation with metabolic parameters in patients with non-alcoholic fatty liver disease | Anastasiia Radchenko | ![]() |
![]() |
|||
THU-050 | The prevalence of non-alcoholic fatty liver disease in the United Kingdom: a systematic review and meta-analysis | Yusef Alenezi | ![]() |
![]() |
|||
THU-051 | Health-related quality of life is impaired in people living with HIV and hepatic steatosis | Maurice Michel | ![]() |
![]() |
|||
THU-053 | Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: korean military population-based cross-sectional study | Jaejun Lee | ![]() |
![]() |
|||
FRI-053 | The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD | Magnus Holmer | ![]() |
![]() |
|||
THU-055 | Association of non-alcoholic fatty liver disease and fibrosis with incident dementia and cognitive function: the Rotterdam Study | Laurens Van Kleef | ![]() |
![]() |
|||
FRI-056 | Ectopic fat deposition in the liver and pancreas and the presence of excess visceral adipose tissue significantly increase hospitalisation risk following COVID-19 | Tom Waddell | ![]() |
![]() |
|||
FRI-059 | Knowledge of liver fibrosis stage among adults with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis improves adherence to life style changes | Jeffrey Lazarus | ![]() |
![]() |
|||
THU-060 | The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients | Marta Freitas | ![]() |
![]() |
|||
FRI-061 | Independent determinants of CAP values in healthy individuals with dysmetabolism | Cristiana Bianco | ![]() |
![]() |
|||
FRI-063 | Correlations of 2D-Shear wave and transient elastography liver stiffness measurements in patients with non-alcoholic fatty liver disease | Dimitrios Karagiannakis | ![]() |
![]() |
|||
THU-064 | Estimating the prevalence of advanced fibrosis due to nonalcoholic fatty liver disease in the United States population | Naim Alkhouri | ![]() |
![]() |
|||
SAT-065 | MPEP, an mGlu5 receptor allosteric modulator, reduces hepatic steatosis in obese high-fat-diet mice | Laura Giuseppina Di Pasqua | ![]() |
![]() |
|||
THU-065 | Non-alcholic fatty liver disease associated liver fibrosis is linked with the severity of coronnary artery disease mediated by systemic inflammation | Xianbin Cai | ![]() |
![]() |
|||
FRI-066 | Incorporating a two-tiered liver fibrosis assessment into annual diabetes review in primary care - 3 year follow up study | Dina Mansour | ![]() |
![]() |
|||
FRI-073 | High prevalence of multi-organ steatosis and fibroinflammation, identified by multi-parametric magnetic resonance imaging, in people with type 2 diabetes | Nicole Eichert | ![]() |
![]() |
|||
THU-077 | Assessment of the prevalence of nonalcoholic fatty liver disease, its severity, and comorbidities in lean americans: national health and nutrition examination surveys (NHANES) with transient elastography assessment from 2017 to 2018 | Emily Truong | ![]() |
![]() |
|||
THU-084 | The association between nonalcoholic fatty liver disease and insulin resistance within normal glucose level population | chun-yi Wang | ![]() |
![]() |
|||
THU-090 | Nonalcoholic fatty liver disease impcat on cardiovascular disease death: a population-based study | Chaonan Jin | ![]() |
![]() |
|||
FRI-091 | Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study | David Marti-Aguado | ![]() |
![]() |
|||
SAT-091 | GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD) | Rajamannar Thennati | ![]() |
![]() |
|||
FRI-093 | Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis | Tian Lan | ![]() |
![]() |
|||
THU-100 | Prevalence of non-alcoholic steatohepatitis in patients undergoing laparoscopic cholecystectomy for gallstone with non-alcoholic fatty liver disease | Utpal Anand | ![]() |
![]() |
|||
SAT-104 | The effect of glucagon on rates of hepatic mitochondrial oxidation and pyruvate carboxylase flux in man assessed by positional isotopomer tracer analysis (PINTA) | Kitt Petersen | ![]() |
![]() |
|||
SAT-115 | Oxygen-nutrient mismatch: a novel concept to explain how Obeticholic acid benefits NASH treatment | Gerond Lake-Bakaar | ![]() |
![]() |
|||
FRI-120 | The Fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients | Leen Heyens | ![]() |
![]() |
|||
SAT-122 | Efficacy and mechanism of time-restricted fasting in non-alcoholic liver disease | Jiang Deng | ![]() |
![]() |
|||
FRI-125 | FIB-4 combined with positron emission tomography biomarkers detects fibrotic NASH | Souvik Sarkar | ![]() |
![]() |
|||
SAT-127 | Spontaneous and drug-induced histological changes in nonalcoholic steatohepatitis: an assessment by meta-analysis of trials | Grazia Pennisi | ![]() |
![]() |
|||
SAT-137 | Hepatocyte-specific JNK signaling is protective during progression of NASH | Julia Piche | ![]() |
![]() |
|||
SAT-141 | The effects of dietary vitamin E intake on NAFLD and sex differences in serum metabolic profile | Carolin Schneider | ![]() |
![]() |
|||
FRI-148 | Preclinical evaluation of the calpain inhibitor BLD-3051 as a therapeutic strategy for liver fibrosis | Ravi Rajagopalan | ![]() |
![]() |
|||
FRI-149 | Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery | Toshifumi Sato | ![]() |
![]() |
|||
THU-152 | The therapeutic effect of Lactobacillus plantarum on metabolic phenotypes in non-alcoholic fatty liver disease mice model | Dong Yun Kim | ![]() |
![]() |
|||
FRI-153 | Dual roles of PSMP/MSMP in the progression of hepatic fibrosis and hepatocellular carcinoma | Shaoping She | ![]() |
![]() |
|||
THU-153 | Stool microbiota, compared to salivary microbiota, show more extensive correlations with plasma metabolites in decompensated cirrhosis in a multinational cirrhosis cohort | I. Jane Cox | ![]() |
![]() |
|||
FRI-154 | NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model | Sofia Mayans | ![]() |
![]() |
|||
THU-155 | Mitochondrial hyperactivation determines a transferable protective gut microbiota profile in metabolic-associated fatty liver disease development | María Juárez-Fernández | ![]() |
![]() |
|||
FRI-162 | Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB | Olivia Wegrzyniak | ![]() |
![]() |
|||
FRI-163 | Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece | Konstantinos Manganas | ![]() |
![]() |
|||
THU-164 | Dynamics of the gut-liver axis in rats with varying fibrosis severity | Hongyan Xiang | ![]() |
![]() |
|||
FRI-166 | Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH | Haeng Ran Seo | ![]() |
![]() |
|||
FRI-172 | The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model | Christian Molina-Aguilar | ![]() |
![]() |
|||
FRI-178 | Multicenter external validation of FIB-6: a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with MAFLD | Gamal Shiha | ![]() |
![]() |
|||
THU-178 | Predictive immune biomarkers to safely discontinue nucleos(t)ide analogue treatment in HBeAg negative chronic hepatitis B (NUC-B study) | Sandra Phillips | ![]() |
![]() |
|||
THU-179 | MAIT-cells in blood are associated with a higher risk of infection in patients with cirrhosis | Hannes Hagstrm | ![]() |
![]() |
|||
SAT-185 | The identification and characterization of novel bile acid-derived Farnesoid X Receptor agonists | Dannielle Kydd-Sinclair | ![]() |
![]() |
|||
FRI-186 | Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis | Alexandru Popa | ![]() |
![]() |
|||
THU-189 | Multi-omics analysis of human livers reveals variation in intrahepatic inflammation across chronic hepatitis B infection phases | Andre Boonstra | ![]() |
![]() |
|||
THU-190 | Liver cirrhosis and cirrhosis etiology impacts the circulating immune mediators of early stage hepatocellular carcinoma | Andre Boonstra | ![]() |
![]() |
|||
FRI-201 | Telomerase-null mice display defective immune activation following the induction of liver fibrosis with S. mansoni | Willian Gomes | ![]() |
![]() |
|||
FRI-206 | LncRNA XR_592974.2 and circRNA _2599 regulated hypoxic stress response in hepatic stellate cells by targeting the miRNA-145/JMY/P53 pathway | Dan Zhou | ![]() |
![]() |
|||
FRI-210 | Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study | Lei Ling | ![]() |
![]() |
|||
FRI-217 | Metabolomic profiling of capillary dry blood samples for the differential diagnoses of hepatocellular carcinoma and liver diseases | Philipp Brunnbauer | ![]() |
![]() |
|||
THU-217 | Reducing the risk of liver cirrhosis and hepatocellular carcinoma after treatment for smoking cessation in patients with chronic hepatitis B or C infection: a 12-year follow-up study | Yuan Tsung Tseng | ![]() |
![]() |
|||
THU-219 | Hepatocellular carcinoma screening trends in individuals with cirrhosis in North Carolina | Christine Hsu | ![]() |
![]() |
|||
FRI-220 | Diagnostic accuracy of non-invasive imaging modalities for the diagnosis of liver cirrhosis compared to histological assessment in a clinical setting | Mira Thing | ![]() |
![]() |
|||
FRI-221 | Use of Fibrosis-4 (FIB-4) in liver fibrosis screening: which thresholds to choose? | denis ouzan | ![]() |
![]() |
|||
THU-221 | Rethinking the management of chronic hepatitis B in the context of rural sub-saharan Africa: results from a social justice mixed methods study in rural Senegal (the AmBASS-PeCSen study) | Marion Coste | ![]() |
![]() |
|||
FRI-224 | Development and validation of a hepatic vascular geometrical model for noninvasive diagnosis of clinically significant portal hypertension in cirrhosis (CHESS1802) | Chengyan Wang | ![]() |
![]() |
|||
THU-226 | Low health literacy is associated with higher healthcare service utilisation and costs among patients with cirrhosis | Elizabeth Powell | ![]() |
![]() |
|||
SAT-229 | Outcomes of living liver donors are worse than those of matched healthy controls: nationwide cohort study | Jong Man Kim | ![]() |
![]() |
|||
SAT-230 | Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study | Xavier Verhelst | ![]() |
![]() |
|||
FRI-231 | Shear wave elastography is a useful and accurate tool to triage patients with acute liver failure syndromes | Francesca M Trovato | ![]() |
![]() |
|||
SAT-231 | Liver transplantation for complications of hepatoportal sclerosis | Andrew Keaveny | ![]() |
![]() |
|||
THU-231 | HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain | Camila A Picchio | ![]() |
![]() |
|||
SAT-232 | Discordance in categorization of acute-on-chronic-liver-failure in the national transplant database | Brian Lee | ![]() |
![]() |
|||
THU-232 | Community-based HBV testing among west african migrants in greater Barcelona, Spain increases linkage to specialist care and vaccination: the HBV-COMSAVA model | Camila A Picchio | ![]() |
![]() |
|||
SAT-233 | Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients | Valentina Cossiga | ![]() |
![]() |
|||
SAT-236 | Formal referral networks optimise patient ion for liver transplantation | Oliver Tavabie | ![]() |
![]() |
|||
THU-237 | Real life pooling of plasma samples for hepatitis C RNA detection as a screening strategy of hepatitis C active chronic infection | Federico Garcia Garcia | ![]() |
![]() |
|||
THU-238 | Epidemiology of hepatocellular carcinoma in Portugal | Mario Jorge Silva | ![]() |
![]() |
|||
THU-242 | Hepatitis C care cascade analysis among adult women in Georgia | Ketevan Stvilia | ![]() |
![]() |
|||
THU-244 | Could a multi-target blood test make hepatocellular carcinoma surveillance programs more effective? A modelling-based virtual trial | Jagpreet Chhatwal | ![]() |
![]() |
|||
SAT-246 | The outcome of living donor versus deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis | Beshoy Elkomos | ![]() |
![]() |
|||
SAT-251 | Use of statins after liver transplantation is associated with improved survival: results of a nationwide study | Chiara Becchetti | ![]() |
![]() |
|||
THU-255 | A novel hepatitis C intervention in Denmark to test and treat people who inject drugs | Jeffrey Lazarus | ![]() |
![]() |
|||
SAT-257 | Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation - a prospective six month follow up | Theresa Kirchner | ![]() |
![]() |
|||
SAT-261 | Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients | Manuel Mendizabal | ![]() |
![]() |
|||
THU-262 | Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis | Binu John | ![]() |
![]() |
|||
SAT-262 | Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time | Claire Harrington | ![]() |
![]() |
|||
THU-264 | The protective role of dairy protein on sarcopenic obesity in middle-aged and older women: a community-based, 12-year, prospective cohort study | Jun-Hyuk Lee | ![]() |
![]() |
|||
SAT-266 | The prognostic effect of adequate lymphadenectomy in clinically node-negative patients undergoing liver resection for intrahepatic cholangiocarcinoma | Carlo Sposito | ![]() |
![]() |
|||
THU-285 | Measuring the alcohol related hospital burden in Ireland and the impact of Minimum Unit Pricing (MUP) | Tobias Maharaj | ![]() |
![]() |
|||
FRI-288 | Fontan associated liver disease: A cohort review into the prevalence of portal hypertension | Hannah Donnelly | ![]() |
![]() |
|||
SAT-288 | Liver transplant recipients have a higher incidence of lung cancer than general population | Jose Ignacio Herrero | ![]() |
![]() |
|||
SAT-297 | Does m-RNA Vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients? | Ubaldo Visco Comandini | ![]() |
![]() |
|||
SAT-299 | Clinical significance of three-dimensional printing of the portal venous system in patients with extrahepatic portal hypertension | Binita Chaudhary | ![]() |
![]() |
|||
THU-301 | Hepatitis E Virus Capsid Antigen (HEV-Ag): a practical diagnostic biomarker in the HEV outbreak scenerio | Simon Lytton | ![]() |
![]() |
|||
FRI-302 | Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial | Tafireyi Marukutira | ![]() |
![]() |
|||
SAT-304 | Managing HBV/HDV co-infection post liver transplant - Exploring a decade of experience | Almuthana Mohamed | ![]() |
![]() |
|||
FRI-304 | Effectiveness of a central monitoring system for the continuum of care of hepatitis C in Brazil during COVID-19 pandemic | Paulo Bittencourt | ![]() |
![]() |
|||
FRI-305 | Retrieval of HCV patients lost to follow-up as a strategy as a strategy for hepatitis C microelimination: results of a brazilian multicentric study | Paulo Bittencourt | ![]() |
![]() |
|||
SAT-306 | Outcome of choledochal cysts with intrahepatic involvement (type IV-A) after extrahepatic cyst excision and roux-en-Y hepaticojejunostomy in adults | Utpal Anand | ![]() |
![]() |
|||
FRI-310 | The korean hepatitis C virus care cascade in a tertiary institution: current status and changes in testing, link to care, and treatment | Jonggi Choi | ![]() |
![]() |
|||
FRI-311 | Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy | David Kaplan | ![]() |
![]() |
|||
THU-312 | A versatile small animal immunocompromised model for chronic hepatitis E | Siddharth Sridhar | ![]() |
![]() |
|||
SAT-319 | The crucial role of PARP poly(ADP-ribose polymerase on the post-ischemic liver injury and inflammation | Michitaka Ozaki | ![]() |
![]() |
|||
THU-327 | Therapeutic suppression of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones | Lena Allweiss | ![]() |
![]() |
|||
FRI-337 | From extensive to intensive screening, co-operations model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China | Qing Lin | ![]() |
![]() |
|||
FRI-345 | Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response - data from the german hepatitis C-registry (DHC-R) | Stefan Mauss | ![]() |
![]() |
|||
FRI-348 | Suboptimal follow-up, high re-infection, and drug-related death, among HCV-treated people who inject drugs in Tayside, Scotland | Christopher Byrne | ![]() |
![]() |
|||
SAT-349 | Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study | Qing-Lei Zeng | ![]() |
![]() |
|||
FRI-350 | Five-years follow-up of cured HCV patients with or without cirrhosis under real-world interferon-free therapy | Robert Flisiak | ![]() |
![]() |
|||
SAT-350 | Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events | Chau-Ting Yeh | ![]() |
![]() |
|||
THU-352 | Hepatitis B Delta: assesment of knowledge and practices of French non academic hepato-gastroenterologists | Jean-Franois Cadranel | ![]() |
![]() |
|||
SAT-355 | HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection | Lisa Sandmann | ![]() |
![]() |
|||
SAT-356 | Management of chronic hepatitis B virus infection within a large integrated health care setting: treatment patterns among kaiser permanente members in southern california, 2008 - 2019 | Deborah Malden | ![]() |
![]() |
|||
THU-357 | The Comparison of Tenofovir Alafenamide Fumarate with Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Transmission in Mothers with High Viral Load: A Retrospective Cohort Study | Yunxia Zhu | ![]() |
![]() |
|||
THU-360 | Liver fibrosis burden determines risk of hepatocellular carcinoma among patients with hepatitis B surface antigen seroclearance | Lung-Yi Mak | ![]() |
![]() |
|||
THU-361 | Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States | Robert Wong | ![]() |
![]() |
|||
SAT-362 | Therapeutic vaccination with CLB-3000 in a mouse model of chronic hepatitis B induces anti-HBs responses associated with functional cure | Aileen Rubio | ![]() |
![]() |
|||
THU-364 | Suboptimal glycemic control is associated with adverse clinical outcomes in patients with chronic hepatitis B and diabetes mellitus | Lung-Yi Mak | ![]() |
![]() |
|||
THU-365 | Statin use and surface antigen loss in patients with chronic hepatitis B | Shahed Iqbal | ![]() |
![]() |
|||
THU-366 | Patient engagement in hepatitis B clinical trials: HBV cure is a motivation for participation in all ethnically diverse patients | Almuthana Mohamed | ![]() |
![]() |
|||
SAT-369 | Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China) - 3.5 years data update | Chan Xie | ![]() |
![]() |
|||
THU-371 | A decision-making model for prediction of a stable disease course in chronic hepatitis B patients | Imri Ofri | ![]() |
![]() |
|||
SAT-374 | Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a HEllenic multicenter ReAl-life CLInical Study (HERACLIS-TAF) | George Papatheodoridis | ![]() |
![]() |
|||
THU-378 | Impact of hepatitis B virus infection on liver-related death among people tested for HBV in British Columbia: results from a large longitudinal population-based cohort study | Makuza Jean Damascene | ![]() |
![]() |
|||
SAT-378 | Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B | Jihye Lim | ![]() |
![]() |
|||
FRI-383 | Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool | David Burger | ![]() |
![]() |
|||
FRI-389 | HCV-RNA viral load fingerstick assay as a simplified strategy for screening and linkage to care of people who use drugs attending 3 french addiction centers | Denis Ouzan | ![]() |
![]() |
|||
FRI-390 | Pangenotypic and genotype-specific antivirals in the treatment of genotype 4 infected patients with HIV coinfection | Dorota Zarebska-Michaluk | ![]() |
![]() |
|||
FRI-391 | Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure | Julia Dietz | ![]() |
![]() |
|||
THU-392 | Time for universal screening for hepatitis D? A study describing screening patterns, characteristics and outcomes of hepatitis D virus infection | Rohit Nathani | ![]() |
![]() |
|||
SAT-399 | Early antiviral efficacy of tenofovir alafenamide fumarate in the initial treatment of chronic hepatitis B patients with normal ALT | Xin Chi | ![]() |
![]() |
|||
THU-402 | Prevalence of HBV infection and receiving antiviral treatment for eligible patients in blood relatives from clustering families of HBV infection with unfavorable prognoses and cascading of care linked to treatment in West China | yuan yang | ![]() |
![]() |
|||
FRI-406 | Effectiveness of pangenotypic retreatment of HCV infection after prior failure of pangenotypic therapies | Robert Flisiak | ![]() |
![]() |
|||
SAT-420 | Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide - an interim analysis | Pin-Nan Cheng | ![]() |
![]() |
|||
SAT-432 | Low level of HBcrAg is beneficial to functional cure obtained with pegylated interferon therapy in inactive HBsAg carriers | Zhenhuan Cao | ![]() |
![]() |
|||
THU-438 | Analyses of obeticholic acid treatment retention in UK patients based on medicine delivery data | Carl Gibbons | ![]() |
![]() |
|||
SAT-442 | Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos(t)ide analogue: 96-week results from a prospective multinational study | Eiichi Ogawa | ![]() |
![]() |
|||
THU-444 | Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study | Marcus Maximilian Mcke | ![]() |
![]() |
|||
SAT-445 | Generation and functional analsis of spacer modified HBV-specific chimeric antigen receptors that harbor a Fab fragment as binding domain | Zhe Xie | ![]() |
![]() |
|||
THU-446 | Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality | Rasmine Birn-Rydder | ![]() |
![]() |
|||
SAT-449 | Tenofovir alafenamide fumarate increased lipid levels in hepatitis B virus patients | Wenjuan Zhao | ![]() |
![]() |
|||
THU-463 | The prevalence of primary biliary cholangitis (PBC) is on the rise: a canadian population-based study | Bryce Tkachuk | ![]() |
![]() |
|||
THU-465 | Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis | Ana Barreira | ![]() |
![]() |
|||
THU-477 | Gluco-regulatory disturbances in primary biliary cholangitis and non-alcoholic fatty liver disease compared with healthy individuals | Anne-Sofie Houlberg Jensen | ![]() |
![]() |
|||
FRI-485 | TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis | Lena Stockhoff | ![]() |
![]() |
|||
SAT-486 | Evaluation of Interleukin-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis | Simon Johannes Gairing | ![]() |
![]() |
|||
SAT-488 | The effect of sarcopenia on survival of patients with cirrhosis: a systematic review and meta-analysis | Xinxing Tantai | ![]() |
![]() |
|||
FRI-489 | Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: relation to severity? | Puria Nabilou | ![]() |
![]() |
|||
SAT-489 | Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients | Muhammad Farooq Hanif | ![]() |
![]() |
|||
SAT-490 | Sarcopenia as a predictor of mortality and complications in cirrhosis patients - A prospective cohort study | NIDHIN DEVADAS | ![]() |
![]() |
|||
FRI-493 | Transjugular intrahepatic portosystemic shunt versus balloon-occluded transvenous obliteration for the management of ectopic varices | Ranya Selim | ![]() |
![]() |
|||
THU-494 | Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis | Jasmohan S Bajaj | ![]() |
![]() |
|||
THU-496 | Renal and circulatory effects of terlipressin in patients with hepatorenal syndrome assessed by magnetic resonance imaging | Puria Nabilou | ![]() |
![]() |
|||
SAT-496 | SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis | Jacqueline OLeary | ![]() |
![]() |
|||
THU-497 | SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality | Robert Wong | ![]() |
![]() |
|||
SAT-497 | Natural history of Hepatic Encephalopathy (HE) in a tertiary referral centre for hepatology | Chiara Mangini | ![]() |
![]() |
|||
SAT-498 | Public knowledge and attitudes toward liver diseases and liver cancer in the brazilian population | Paulo Bittencourt | ![]() |
![]() |
|||
SAT-503 | Risk of herpes zoster infection in patients with cirrhosis: a nationwide population-based study in Korea | DONGSUB JEON | ![]() |
![]() |
|||
SAT-505 | Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis | Tammo Lambert Tergast | ![]() |
![]() |
|||
FRI-508 | Simultaneous large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial | Guohong Han | ![]() |
![]() |
|||
FRI-512 | Personalized preemptive TIPS treatment for patients with Child-Pugh B cirrhosis and acute variceal bleeding by applying individualized of prediction of treatment effect | Guohong Han | ![]() |
![]() |
|||
SAT-513 | Kidney transplant alone recipients with advanced liver disease have similar outcomes to those without advanced liver disease - a single center study of 150 patients | Rohit Nathani | ![]() |
![]() |
|||
FRI-517 | Ruling out varices needing treatment with a non-invasive score in patients with compensated HBV cirrhosis | Giacomo Emanuele Maria Rizzo | ![]() |
![]() |
|||
THU-521 | Use of Tocilizumab in patients with stable Chronic Liver Disease and severe COVID-19 for prevention of Decompensated Cirrhosis, a Prospective, Open-label, Randomized Controlled Trial. | Luis Alejandro Rosales Renteria | ![]() |
![]() |
|||
THU-526 | Increased platelet aggregation in decompensated cirrhosis indicates higher risk of further decompensation and liver-related mortality | Alberto Zanetto | ![]() |
![]() |
|||
SAT-534 | MYOSTEATOSIS is associated with SARCOPENIA, FRAILTY and FAT BODY COMPOSITION ABNORMALITIES in LIVER CIRRHOSIS | Alexandra Alexopoulou | ![]() |
![]() |
|||
THU-537 | The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients | Sophie Allen | ![]() |
![]() |
|||
SAT-538 | Effect of hepatitis B virus treatment on all causes and liver-related death among patients living with HBV with cirrhosis in British Columbia in a population-based cohort study | Makuza Jean Damascene | ![]() |
![]() |
|||
FRI-543 | Cancer-associated fibroblasts nurture LGR5 marked liver tumour-initiating cells and promote their metastasis | Qiuwei Pan | ![]() |
![]() |
|||
FRI-545 | Identification of new dominant neoantigens in hepatocellular carcinoma based on a single plasmid system with co-expressing patients HLA and antigen | Pu Chen | ![]() |
![]() |
|||
FRI-546 | Polypeptide N-acetylgalactosaminyltransferase 14 mediated O-glycosylation on prohibitin-2 serine 161 modulates cell growth, migration and drug susceptibility in hepatocellular carcinoma | Chau-Ting Yeh | ![]() |
![]() |
|||
FRI-547 | Gut bacteria modulate anti-tumour immunity in patients with hepatocellular carcinoma | Antonio Riva | ![]() |
![]() |
|||
FRI-549 | Role of autophagy-mediated neuropilin-1 degradation on lenvatinib efficacy in human hepatocarcinoma | Paula Fernández-Palanca | ![]() |
![]() |
|||
THU-550 | miRNA associated with systemic inflammation may have prognostic utility in predicting decompensation in patients with chronic liver disease | Oliver Tavabie | ![]() |
![]() |
|||
FRI-552 | Hippo inactivation drives BMI1-associated proliferative hepatocarcinogenesis in chronic hepatitis B virus infection | Ruth Broering | ![]() |
![]() |
|||
FRI-554 | Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis | Leticia Colyn | ![]() |
![]() |
|||
SAT-556 | Validation of a glycomics-based test associated with risk of HCC development in cirrhosis | Xavier Verhelst | ![]() |
![]() |
|||
SAT-559 | NanoView EV Chip-based profiling in liver cancer differentiation - HCC from intrahepatic CCA - small EVs vs large EVs | Bingduo Wang | ![]() |
![]() |
|||
SAT-562 | Diagnostic accuracy of protein-induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) among caucasian cirrhotic patients with or without diagnostic serum a-fetoprotein (AFP) levels | antonia syriha | ![]() |
![]() |
|||
FRI-563 | High plasma level of osteopontin, a potential biomarker in hepatocellular carcinoma, is associated with weakened anti-tumour immunity | Tengfei Si | ![]() |
![]() |
|||
SAT-565 | On treatment alpha-fetoprotein reductions predict immunotherapy efficiency in patients with hepatocellular carcinoma | Bernhard Scheiner | ![]() |
![]() |
|||
SAT-567 | Non-alcoholic fatty liver disease and increased risk of incident primary liver tumours: a meta-analysis of observational cohort studies | Andrea Dalbeni | ![]() |
![]() |
|||
SAT-569 | Machine learning algorithm based on dual screening for hepatocellular carcinoma using circulating cell-free DNA and cfDHCC scoring system | HYUK SOO EUN | ![]() |
![]() |
|||
THU-570 | Textbook outcome after major hepatectomy for perihilar cholangiocarcinoma - definitions and influencing factors | Christian Benzing | ![]() |
![]() |
|||
SAT-576 | A novel hierarchical fusion strategy of deep learning networks to detect hepatocellular carcinoma from dynamic computed tomography images | I-Cheng Lee | ![]() |
![]() |
|||
THU-577 | Incidence of hepatocellular carcinoma reduced in chronic hepatitis B patients treated with entercavir plus Biejia-Ruangan: extended follow-up of a multicenter, randomised, double-blinded, placebo-controlled trial | Dong Ji | ![]() |
![]() |
|||
FRI-578 | ACSL4-dependent ferroptosis promotes HCC progression | Julia Piche | ![]() |
![]() |
|||
THU-582 | Implementation of a new prognostic scoring system after major hepatectomy in curative intent for perihilar cholangiocarcinoma | Christian Benzing | ![]() |
![]() |
|||
SAT-585 | Multiparametric ultrasound approach using a tree based decision classifier for the inconclusive focal liver lesions evaluated by contrast enhanced ultrasound | Tudor-Voicu Mpga | ![]() |
![]() |
|||
FRI-586 | Different immunological microenvironment in patients with different cirrhosis etiology and hepatocellular carcinoma | Andrea Dalbeni | ![]() |
![]() |
|||
SAT-592 | Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different BCLC stages undergoing curative hepatectomy | Grace Wong | ![]() |
![]() |
|||
THU-594 | The influence of fasting on tumor-targeted drug delivery | Svea Becker | ![]() |
![]() |
|||
SAT-596 | Germline Genetic Risk Factors for the Development of Hepatocellular Carcinoma among Patients with Cirrhosis: A Genome-Wide Association Study of U.S. Veterans | David Kaplan | ![]() |
![]() |
|||
FRI-999 | Test 1 | Art Vandeley | ![]() |
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|